|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/00 | |
| A61P 31/12 | |||
| A61P 31/18 | |||
| A61P 31/22 | |||
| G01N 33/53 | |||
| C07K 16/28 |
| (11) | Number of the document | 2397155 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11162667.7 |
| Date of filing the European patent application | 2006-06-08 | |
| (97) | Date of publication of the European application | 2011-12-21 |
| (45) | Date of publication and mention of the grant of the patent | 2017-12-13 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 688872 P | 2005-06-08 | US |
| (72) |
Freeman, Gordan, US
Sharpe, Arlene, US
Dorfman, David M., US
Ahmed, Rafi, US
Barber, Daniel, US
Wherry, E. John, US
|
| (73) |
President and Fellows of Harvard College,
17 Quincy Street, Cambridge, MA 02138,
US
The Brigham and Women`s Hospital, Inc., 75 Francis Street, Boston, MA 02115, US Dana-Farber Cancer Institute, Inc., 450 Brookline Avenue, Boston, MA 02215, US Emory University, 1599 Clifton Road NE 4th Floor, Atlanta, GA 30322, US |
| (54) | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway |
| Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway |